- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00941356
Evaluation of the Efficacy of Bio-K+ Cl-1285® In the Nasal Decolonization of Methicillin Resistant Staphylococcus Aureus (MRSA) Carrier Patients (MRSA)
A Single Center, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of Bio-K+ Cl-1285® In the Nasal Decolonization of Methicillin Resistant Staphylococcus Aureus (MRSA) Carrier Patients
Trial Objectives:
Primary objective:
- To evaluate the efficacy of Bio-K+CL1285® in patients with Methicillin-Resistant S. aureus (MRSA) nasal colonization by comparing the MRSA decolonization following either Bio-K+CL1285® or placebo treatment.
Secondary objective:
- To evaluate the safety profile of Bio-K+CL1285®.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Design:
Double-blind, randomized (1:1 randomization), placebo-controlled, single center Canadian study.
Patients will be randomly assigned to one of the two study products. A randomization schedule will be generated by the sponsor for each participating centre. This schedule will link patient identification numbers to one of the two study products allocated at random. The schedule will be prepared on a 1:1 randomization ratio.
The study products will be labelled with the patient identification number. Patients have to be randomized in the order in which they qualify from the screening phase for inclusion in the study.
Patients withdrawn from the study retain their patient number if already given. New patients must always be allotted a new identification number (PIN).
Study Duration:
The duration of patient participation in the study will be between 22 and 23 days. The overall duration of the study is expected to be approximately 10 months; with subject recruitment proposed to start in March 2009, the last follow-up visit is expected in May 2010. The actual overall study duration or subject recruitment period may vary.
Number of Sites (inside and outside of Canada):
One center in the province of Quebec will be involved in the study.
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Quebec
-
Terrebonne, Quebec, Canada, J6V 2H2
- Pierre Le Gardeur Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female patients having ≥18 years of age
- Women of child bearing capacity who are not pregnant at the moment of screening (Pregnancy test done on-site) and agree to use an acceptable form of birth control for the duration of the study (e.g. condom, oral contraceptives, etc.) are allowed to participate.
- Patients must have nasal MRSA colonization confirmed with MRSA positive culture as assessed during the screening visit without any clinical signs or symptoms of infection.
- Laboratory test results within the normal ranges.
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- Patients treated for nasal MRSA decolonization in the last 6 months;
- Current infection with MRSA;
- Ongoing or active infection;
- Daily probiotic/ fermented milk or Yogurt use;
- Known to have shown a previous reaction, including anaphylaxis, to any substance in composition of the study agent (capsules);
- Ongoing or recent use of antibiotics in the 30 days prior to the study agent administration;
- Pregnancy, breastfeeding;
- Regular use of nasal agents;
- Uncontrolled intercurrent illness, including situations that would limit compliance with study requirements;
- Patients with open wounds
- Immunosuppressive therapy or any health condition causing inmunosuppression (Including Haematological malignancies, AIDS);
- Ostomized patients, parenteral nutrition users;
- Patients with current vascular access (catheter) or planned to have installed a vascular access (catheter) or any prosthesis during the study period.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: 2
placebo devoid of bacteria
|
2 capsules per day before breakfast
|
Experimental: 1
Bio-K+ CL1285 contains 50 billion of live bacteria
|
2 capsules per day before breakfast
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Frequency of subjects with MRSA decolonization
Time Frame: 21 days
|
21 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate the secondary effects (incidence rate of non-serious ans serious adverse events)associated to the administration of the study product
Time Frame: 21 days
|
21 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Dr Pierre-Jean PM Maziade, MD, Pierre Le Gardeur Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CL1285-MRSA-M03
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on MRSA Colonization
-
Hvidovre University HospitalRecruiting
-
Hacettepe UniversityThe Scientific and Technological Research Council of TurkeyCompletedMRSA Colonization | VRE ColonizationTurkey
-
Heidelberg UniversityCompleted
-
Massachusetts General HospitalCompletedMRSA ColonizationUnited States
-
Rothman Institute OrthopaedicsUnknown
-
University of British ColumbiaUnknownNasal Colonization With MRSA BacteriaCanada
-
University of TennesseeUnited States Department of DefenseCompleted
-
Hunter Holmes Mcguire Veteran Affairs Medical CenterCenters for Disease Control and Prevention; Sage Products, Inc.UnknownMRSA Infection | MRSA Colonization | VRE Infection | VRE Colonization | Nosocomial BacteremiaUnited States
-
Hunter Holmes Mcguire Veteran Affairs Medical CenterJohns Hopkins University; Washington University School of Medicine; Weill Medical... and other collaboratorsCompletedMRSA Infection | MRSA Colonization | VRE Infection | VRE Colonization | Nosocomial Bacteremia | Nosocomial FungemiaUnited States
-
B. Braun Medical SATerminatedMRSA - Methicillin Resistant Staphylococcus Aureus Infection | MRSA ColonizationSpain
Clinical Trials on Bio-K+ CL1285
-
Bio-K Plus International Inc.ethica Clinical Research Inc.Completed
-
Bio-K Plus International Inc.Sprim Advanced Life SciencesSuspendedRecurrent Clostridium Difficile InfectionUnited States
-
Bio-K Plus International Inc.Sprim Advanced Life SciencesCompleted
-
McMaster UniversityUnknown
-
Bio-K Plus International Inc.Centre hospitalier de l'Université de Montréal (CHUM)TerminatedClostridium Difficile Infection | Antibiotic Associated DiarrheaCanada
-
McMaster UniversityRecruitingIrritable Bowel SyndromeCanada
-
Bio-K Plus International Inc.Sprim Advanced Life SciencesCompletedClostridium Difficile-Associated Diarrhea | Antibiotic-Associated Diarrhea
-
Bio-K Plus International Inc.JSS Medical Research Inc.CompletedDiarrhea | Clostridium InfectionsCanada
-
Tel-Aviv Sourasky Medical CenterUnknown